The AJT Report

American Journal of Transplantation

Volumn 14, Issue 10, 2014, Pages 2195-2196

  Pondrom, Sue ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; TRANSPLANTATION;

COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE RATIONING; HEALTH POLICY; HEALTH PRIORITIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; TRANSPLANTATION;

EID: 84929515861     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12995     Document Type: Editorial

References (6)

1. Vo, AA, Petrozzino, J, Yeung, K, Sinha, A, Kahwaji, J, Peng, A, et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation 95 (2013), 852–858.
2. Montgomery, RA, Lonze, BE, King, KE, Krause, ES, Kucirka, LM, Locke, JE, et al. Desensitization of HLA-incompatible kidney recipients and survival. N Engl J Med 365 (2011), 318–326.
3. Snyder, LD, Gray, AL, Reynolds, JM, Arepally, GM, Bedoya, A, Hartwig, MG, et al. Antibody desensitization therapy in highly sensitized lung transplant candidates. Am J Transplant 14 (2014), 849–856.
4. Kozlowski, T, Andreoni, K, Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time?. Ann Transplant 16 (2011), 19–25.
5. Alachkar, N, Lonze, BE, Zachary, AA, Holecheck, MJ, Schillinger, K, Cameron, AM, et al. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 94 (2012), 165–171.
6. Jordan, SC, Vo, A, Lai, CH, Reinsmoen, N, Defining the benefits of desensitization therapy. Transplantation 95 (2013), e31–e32.